Australia is on the cusp of a transformative shift in Alzheimer’s disease care, with the launch of a pioneering new blood test that can detect early signs of the condition up to two decades before patients begin showing noticeable symptoms. Developed as part of a new collaborative initiative between Neuroscience Research Australia (NeuRA) and Roche Diagnostics Australia, the test will anchor the newly launched Asia-Pacific Centre of Excellence for Alzheimer’s Disease Diagnosis in Sydney, formally opened by Federal Minister for Health and Ageing Mark Butler.
For decades, one of the most intractable barriers to effective Alzheimer’s care has been delayed or uncertain diagnosis. Current gold-standard confirmation methods—PET brain scans and lumbar punctures to collect cerebrospinal fluid—are costly, invasive, and largely inaccessible outside major metropolitan centers. Many patients wait years for a definitive diagnosis, by which time disease-modifying treatments that work only in early stages are no longer effective. The new blood-based test upends this status quo: it delivers results in as little as 18 minutes, matches the accuracy of traditional testing methods, and can identify Alzheimer’s-related protein changes decades before cognitive symptoms emerge.
Associate Professor Emma Devenney, a leading researcher on the project, explained that the test targets key biomarkers linked to Alzheimer’s pathology: pTau181, pTau217, and the ApoE4 genetic risk marker. “These blood-based biomarkers let us confirm the presence of the proteins that cause Alzheimer’s far earlier than current diagnostic pathways,” Devenney noted in an interview with NewsWire. “That early certainty is life-changing for patients. Right now, the average time from a patient first noticing symptoms to getting a dementia diagnosis is around three years—for some, it’s even longer. By that point, many can’t access the treatments that slow progression, which only work in early-stage disease.”
The experience of Nell Hawe, a Port Macquarie grandmother living with young-onset Alzheimer’s, underscores the harm of diagnostic delay. Hawe first developed symptoms at age 48, but it took four years for her to receive a diagnosis, after doctors repeatedly dismissed her early cognitive changes as stress and menopause-related changes. “I could have started treatment years earlier, which might have slowed how quickly the disease progressed,” Hawe said. She is part of the *Think Again* public awareness campaign run by news.com.au and *The Australian*, and emphasized that early, accessible diagnosis would transform outcomes for thousands of Australian families. “The waiting for a diagnosis is the most frustrating part for so many people. A simple blood test that gives answers quickly is just amazing,” she added.
Roche’s test has already secured a spot on Australia’s Therapeutic Goods Administration registry, marking one of the first approved Alzheimer’s blood tests in the country. For the immediate future, the test will be used primarily to confirm Alzheimer’s pathology for clinical trials run out of the new Sydney centre, but leaders of the project expect broader access for clinical use to become available over the coming months. The centre will also serve as an Asia-Pacific hub for dementia diagnostics research, working alongside partners Eli Lilly Australia to streamline diagnostic and treatment pathways, evaluate new biomarkers, and speed up the translation of emerging research into patient care.
The launch comes as Australia and the broader Asia-Pacific region face an escalating dementia public health crisis. Dementia is already the leading cause of death in Australia, where more than 446,500 people currently live with the condition. Projections indicate that number will surpass 1 million by 2065, with the annual economic cost already exceeding $15.8 billion (corrected from the original $4.7 billion that referenced partial costs) and growing pressure on household caregivers and the public health system. Alzheimer’s accounts for 60 to 70 per cent of all dementia cases globally, yet an estimated 75 per cent of people living with the disease remain undiagnosed. For the Asia-Pacific region, which is home to 20 per cent of the global population, the burden is set to grow even faster: the region is expected to account for more than half of the world’s dementia cases by 2050.
Long-term, the project’s leadership aims to secure Medicare coverage for the blood test, making it widely accessible to patients across regional and metropolitan Australia. For now, patients concerned about cognitive decline are advised to first consult their general practitioner, who can refer them to a specialist for testing once the centre is fully operational. Experts say the breakthrough lays the groundwork for a future shift from late-stage Alzheimer’s care to preventive intervention, a long-sought goal that could drastically reduce the global burden of the disease.